Skip to Main Content

The Department of Justice has started investigating whether drug makers failed to disclose information about a possible carcinogen in versions of a popular heartburn drug called ranitidine, most commonly known as Zantac, that were sold to the U.S. government.

Two companies — Sanofi (SNY) and GlaxoSmithKline (GSK) — disclosed in securities filings last week that they received so-called civil investigative demands in June for information indicating potential violations of the False Claims Act, which suggests authorities are probing whether the drug makers submitted false claims to government agencies for reimbursement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Wasn’t Sanofi the same company that solved the Dengvaxia that causes a lot of death in the Philippines.

    It seems next time I buy any medicine I have to make sure they are not from Sanofi given their questionable business ethics.

  • Could this civil action be a way to generate a rebate for this item from last Friday’s Pharmalitte? “The U.S. government’s Operation Warp Speed effort will provide up to $2.1 billion to Sanofi (SNY) and GlaxoSmithKline (GSK) to fund development and manufacturing of their experimental Covid-19 vaccine.”
    But I’m sure it’s all in the eyes of the Observer?

Comments are closed.